November 4, 2020 -- Avidea Technologies has published preclinical results for its Snap cancer vaccine (Snap CV) in Nature Immunology on November 2 showing how the route of vaccine administration influences the quality of anticancer T-cell responses that affect treatment efficacy.
In preclinical studies, the vaccine induced greater responses of stem-like (TCF1+) tumor antigen-specific CD8+ T cells associated with improved tumor clearance when administered intravenously as compared with more conventional routes of vaccination.
The vaccine was produced on Avidea's Snap CV platform, which allows for the production of targeted patient-specific neoantigens with programmable antigen and immunostimulants loading in self-assembling nanoparticles. The nanoparticles target immune cells that prime anticancer T-cell immunity.
The company has previously demonstrated that cancer vaccines produced on the platform have improved neoantigen-specific CD8+ T-cell responses in mice and primate models when delivered subcutaneously.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
